Products for Research Use Only

Cyclophosphamide

CAT: 0804-HY-17420-02Size: 200 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-17420-02Size:200 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Cyclophosphamide is a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic activity, a immunosuppressant.
CAS Number
50-18-0
UNSPSC
12352005
Hazard Statement
H301, H340, H350, H360
Target
DNA Alkylator/Crosslinker
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Cyclophosphamide.html
Purity
99.90
Solubility
DMSO : 100 mg/mL (ultrasonic) |H2O : 33.33 mg/mL (ultrasonic)
Smiles
ClCCN(CCCl)P1(OCCCN1)=O
Molecular Formula
C7H15Cl2N2O2P
Molecular Weight
261.09
Precautions
H301, H340, H350, H360
References & Citations
[1]Schwartz PS, et al. Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. Mol Pharmacol. 2001 Dec;60 (6) :1268-1279.|[2]al-Jafari AA, et al. Inhibition of human acetylcholinesterase by cyclophosphamide. Toxicology. 1995 Jan 19;96 (1) :1-6.|[3]Harris RN, et al. Carbon tetrachloride-induced increase in the antitumor activity of cyclophosphamide in mice: a pharmacokineticstudy. Cancer Chemother Pharmacol. 1984;12 (3) :167-72.|[4]Liu P, et al. Administration of cyclophosphamide changes the immune profile of tumor-bearing mice. J Immunother. 2010 Jan;33 (1) :53-9.|[5]Dominique A Ramirez, et al. Kinetics of Cyclophosphamide Metabolism in Humans, Dogs, Cats, and Mice and Relationship to Cytotoxic Activity and Pharmacokinetics. Drug Metab Dispos. 2019, 47, 3.|[6]H. Roness, et al. Pharmacological administration of recombinant human AMH rescues ovarian reserve and preserves fertility in a mouse model of chemotherapy, without interfering with anti-tumoural effects. J Assist Reprod Genet. 2019, 36, 9.|[7]Susana Salva, et al. Probiotic Lactobacillus strains protect against myelosuppression and immunosuppression in cyclophosphamide-treated mice. Int Immunopharmacol. 2014, 22, 1.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
ACS Appl Bio Mater. 2023 Oct 16;6 (10) :4413-4420.|ACS Nano. 2025 Feb 4;19 (4) :4672-4683.|Apoptosis. 2025 Jun;30 (5-6) :1331-1350.|Biochem Pharmacol. 2021 Jan:183:114340.|Biology (Basel) . 2025 Jul 8;14 (7) :829.|Biomed Res Int. 2022 Jul 13:2022:8495159.|bioRxiv. 2023 Feb 27:2023.02.27.530263.|bioRxiv. 2025 Sep 21.|Biotechnol Appl Biochem. 2025 Jun 18.|BJOG. 2025 Apr:132 Suppl 2:107-119.|Breast Cancer Res Treat. 2023 Jul;200 (2) :193-201.|Cell Death Dis. 2020 Nov 12;11 (11) :976.|Cell Mol Biol Lett. 2025 Feb 19;30 (1) :21.|Cell Rep Med. 2024 Nov 25:101837.|Cell Rep Med. 2025 Apr 2:102053.|Cell Rep. 2025 Mar 25;44 (4) :115466.|Cell Rep. 2025 Sep 2;44 (9) :116215.|Clin Transl Med. 2025 May;15 (5) :e70336.|Cytotechnology. 2025 Apr;77 (2) :76.|Eur J Pharm Sci. 2024 Jul 21:106860.|Evid Based Complement Alternat Med. 2021 Nov 11;2021:1718709.|Evid Based Complement Alternat Med. 2022 Feb 15;2022:7889199.|Exp Ther Med. 2025 Sep 18;30 (6) :224.|Free Radic Biol Med. 2024 Aug 5:S0891-5849 (24) 00589-6.|Heliyon. 2024 Aug 22;10 (17) :e36664.|Int J Biol Macromol. 2024 Jul 26:134195.|Int J Biol Macromol. 2025 Apr 17;310 (Pt 1) :143312.|Int J Mol Sci. 2023 Feb 14;24 (4) :3818.|J Clin Invest. 2024 Mar 7;134 (10) :e172716.|J Ethnopharmacol. 2025 Jul 14;353 (Pt A) :120294.|J Med Chem. 2025 Mar 27;68 (6) :6339-6360.|J Med Food. 2022 Jul;25 (7) :722-731.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|J Ovarian Res. 2024 Jan 15;17 (1) :18.|Journal of Dermatologic Science and Cosmetic Technology. 2025 Jun.|Life Sci. 2020 Aug 1;254:117590.|Mol Biol Cell. 2023 May 1;34 (5) :ar47.|Nat Commun. 2021 Jan 4;12 (1) :20.|Nat Commun. 2023 Apr 13;14 (1) :2109.|Oncol Res. 2024 May 23;32 (6) :1109-1118.|Open Life Sci. 2023 Jan 10;18 (1) :20220535.|Patent. US20250228895A1.|Pediatr Res. 2025 Feb 20.|Phys Med Biol. 2020 Sep 24;65 (19) :195004.|Phytomedicine. 2025 Jun 20:145:156996.|Phytomedicine. 2025 Nov 29:150:157633.|Pulm Pharmacol Ther. 2023 Jun:80:102202.|Reprod Sci. 2025 Aug 11.|Saudi J Biol Sci. 2023 Aug;30 (8) :103707.|SSRN. 2025 Feb 18.|SSRN. 2025 Oct 30.|Stem Cell Res Ther. 2025 Aug 26;16 (1) :459.|Toxicol Rep. 2025 Sep 9;15:102125.|Cell Biol Int. 2025 May 22.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|Research Square Preprint. 2023 Jul 10.

Chemical Information

Cyclophosphamide

Cyclophosphamide (Hydrated) can cause cancer according to California Labor Code. It can cause developmental toxicity according to an independent committee of scientific and health experts. It can cause female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements.

CAS Number50-18-0
PubChem CID2907
IUPAC NameN,N-bis(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine
Molecular FormulaC7H15Cl2N2O2P
Molecular Weight261.08
XLogP0.6
Topological Polar Surface Area41.6
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count4
Rotatable Bond Count5
Heavy Atom Count14
Formal Charge0
Complexity212
SMILES
C1CNP(=O)(OC1)N(CCCl)CCCl
InChI
InChI=1S/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12)
InChIKey
CMSMOCZEIVJLDB-UHFFFAOYSA-N
Chemical Structure
2D Structure
2D structure of Cyclophosphamide
CAS: 50-18-0
CID: 2907
Formula: C7H15Cl2N2O2P
MW: 261.08
Interactive 3D Structure
Loading 3D structure...
Computed Properties
PropertyValue
Molecular Weight261.08
XLogP30.6
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count4
Rotatable Bond Count5
Exact Mass260.0248201
Monoisotopic Mass260.0248201
Topological Polar Surface Area41.6 Ų
Heavy Atom Count14
Formal Charge0
Complexity212
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count1
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count1
Compound Is CanonicalizedYes